Back to company

Amicus Therapeutics ApS: Financial statements 2024

CVR: 39359340

Amicus Therapeutics ApS (CVR 39359340) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 1,987,087 and a net result of DKK 16,475 compared with DKK 52,221 the year before. That is an increase of 14.7% compared with the year before. Equity amounted to DKK 309,637. The solvency ratio was 9%. The company had 1 employee in the financial year.

Gross Profit
1,987,087 kr.
Profit/Loss
16,475 kr.
Equity
309,637 kr.
Total Assets
3,426,179 kr.
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024-2 mio.16 t.310 t.1
2023-1.7 mio.52 t.355 t.1
2022-1.6 mio.54 t.303 t.1
2021-644 t.19 t.249 t.1
2020-490 t.22 t.230 t.1

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Amicus Therapeutics ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2024

Jessica Alice Stephens-Brown joins the board of Amicus Therapeutics ApSOct 7, 2024

As of October 7, 2024, Jessica Alice Stephens-Brown has joined the board of directors of Amicus Therapeutics ApS.

Ana Rogovic joins the board of Amicus Therapeutics ApSOct 7, 2024

As of October 7, 2024, Ana Rogovic has joined the board of directors of Amicus Therapeutics ApS.

Charlotte Ann Galvin leaves the board of Amicus Therapeutics ApSOct 7, 2024

As of October 7, 2024, Charlotte Ann Galvin has left the board of directors of Amicus Therapeutics ApS.

David Malcolm Lewis leaves the board of Amicus Therapeutics ApSOct 7, 2024

As of October 7, 2024, David Malcolm Lewis has left the board of directors of Amicus Therapeutics ApS.

Ana Rogovic joins Amicus Therapeutics ApS as directorOct 7, 2024

As of October 7, 2024, Ana Rogovic is registered as director of Amicus Therapeutics ApS.

Charlotte Ann Galvin steps down as director of Amicus Therapeutics ApSOct 7, 2024

As of October 7, 2024, Charlotte Ann Galvin has stepped down as director of Amicus Therapeutics ApS.

Amicus Therapeutics ApS: The 2023 annual report is outJun 28, 2024

Amicus Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK 1,732,212, and the net result was DKK 52,221.

David Malcolm Lewis joins the board of Amicus Therapeutics ApSFeb 1, 2024

As of February 1, 2024, David Malcolm Lewis has joined the board of directors of Amicus Therapeutics ApS.

Anita Jane Clifford leaves the board of Amicus Therapeutics ApSJan 31, 2024

As of January 31, 2024, Anita Jane Clifford has left the board of directors of Amicus Therapeutics ApS.

About Amicus Therapeutics ApS

Amicus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Richard Gideon Morris. The company is owned by Amicus Therapeutics UK Ltd.. The company has 2 employees. In 2025, the company reported a gross profit of DKK 1,441,140 and a net result of DKK 115,004 compared with DKK 16,475 the year before. Equity amounted to DKK 424,641.

Other financial years